Chatham, New Jersey, November 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food & Drug Administration has cleared the Investigational New Drug (IND) application for its novel drug candidate TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the treatment of major depressive disorder (MDD), allowing the company to proceed with a planned Phase 2 “HORIZON” study expected to begin in mid-2026.TNX-102 SL represents Tonix’s effort to address the large and urgent unmet need in adult MDD by targeting the often-overlooked role of sleep disturbance associated with depression. Previously approved under the brand TONMYA™ for fibromyalgia, the repurposed formulation now seeks to apply the compound’s unique pharmacologic profile in a first-line monotherapy context. The IND clearance enables Tonix to initiate a key 6-week randomized, placebo-controlled study, enrolling roughly 360 participants across ~30 U.S. sites, thereby marking a significant advancement toward a potential new treatment option for MDD.
Science Significance
Major depressive disorder is a complex psychiatric condition characterised by persistent low mood, loss of interest, disrupted sleep, cognitive impairment and increased risk of suicide and mortality. The scientific ambition behind TNX-102 SL lies in its mechanism of action: a sublingual formulation of cyclobenzaprine designed to address sleep disruption and neurochemical dysregulation associated with depression — specifically targeting multiple receptor systems including 5-HT₂A, α₁-adrenergic, H₁-histaminergic and M₁-muscarinic receptors. Prior data in fibromyalgia and PTSD indicated improvement in depressive symptom scales (e.g., MADRS, BDI-II). By repositioning this molecule for MDD, Tonix explores an innovative approach to depression treatment focused on sleep modulation and neurochemical pathways beyond conventional antidepressants. The potential to deliver a differentiated therapeutic for a lifestyle- and sleep-linked dimension of depression marks a meaningful advancement in neuroscience and clinical psychopharmacology.
Regulatory Significance
The IND clearance from the FDA is a major regulatory milestone, demonstrating that Tonix’s clinical trial protocol, safety data, manufacturing controls, and investigator network meet the stringent requirements for human testing. This step permits initiation of the HORIZON Phase 2 trial, expected to assess TNX-102 SL as a first-line therapy for adult MDD. The clearance positions Tonix favourably for eventual regulatory milestones including pivotal studies, New Drug Application (NDA) submission, and post-market safety surveillance. It illustrates the company’s commitment to Good Clinical Practice (GCP) standards and paves the way for expanded development across neuropsychiatric indications.
Business Significance
Advertisement
From a business perspective, the IND clearance enhances Tonix’s pipeline credibility and investor appeal. The move into MDD — one of the largest therapeutic markets globally — expands Tonix’s commercial horizon beyond its current portfolio. The company’s previous commercialisation of TONMYA for fibromyalgia provides platform experience, while this new programme positions Tonix in the high-value neuroscience/psychiatry segment. Successful progression could lead to strategic partnerships, licensing deals and substantial revenue potential. The clearance also signals to stakeholders the company’s operational readiness and scientific ambition, strengthening its market positioning and growth prospects.
Patients’ Significance
Millions of adults worldwide suffer from MDD and many fail to achieve remission with existing treatments, often experiencing persistent sleep disturbances, cognitive symptoms and reduced quality of life. The development of TNX-102 SL offers hope for a therapy addressing the often-neglected dimension of sleep disruption in MDD, potentially improving both mood and functional outcomes. For patients, the prospect of a sublingual bedtime dose that supports mood, sleep and overall wellbeing represents a meaningful advance in treatment convenience, tolerability and clinical impact.
Policy Significance
The IND clearance aligns with public-health objectives that prioritise innovation in mental health treatment, patient access and reduction of the societal burden of depression. It underscores regulators’ willingness to support novel mechanistic therapies in psychiatry, reflecting broader policy trends that integrate sleep medicine, neuroscience research and mental-health innovation into mainstream regulatory frameworks. The development of TNX-102 SL may also feed into policy discussions on health-system efficiency, mental-health equity and the value of repurposed therapies for high-unmet-need populations.
Tonix’s successful attainment of FDA IND clearance for TNX-102 SL in major depressive disorder marks a pivotal step in advancing a novel therapeutic paradigm for a pervasive psychiatric condition. With a strong scientific foundation, regulatory endorsement and meaningful patient-centric potential, the programme stands out as a high-impact effort within the neuroscience and mental-health ecosystem. As Tonix moves toward its HORIZON Phase 2 trial and beyond, this milestone reflects the convergence of targeted innovation, clinical ambition and hope for millions living with depression.
Source: Tonix Pharmaceuticals press release
